MML Investors Services’s Esperion Therapeutics ESPR Stock Holding History

MML Investors Services’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.8K	Buy	+21,450	New	+$60K	﹤0.01%	3211
2026 Q1	–	Sell	-21,511	Closed	-$79.6K	–	3050
2025 Q4	$79.6K	Sell	21,511 -1,567	-7%	-$5.06K	﹤0.01%	2949
2025 Q3	$61.2K	Buy	23,078 +330	+1%	+$638	﹤0.01%	2858
2025 Q2	$22K	Buy	22,748 +5,595	+33%	+$5.6K	﹤0.01%	2797
2025 Q1	$25K	Buy	17,153 +4,362	+34%	+$8.04K	﹤0.01%	2673
2024 Q4	$28K	Buy	12,791 +413	+3%	+$964	﹤0.01%	2644
2024 Q3	$20K	Buy	12,378 +331	+3%	+$668	﹤0.01%	2557
2024 Q2	$27K	Buy	+12,047	New	+$28.3K	﹤0.01%	2457

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

MML Investors Services's ESPR Position: Q2 2026 in Review

MML Investors Services opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 21,450 shares worth $67.8K. The stake represents ﹤0.01% of the portfolio and ranks #3211 among its holdings. This is a return to the name: MML Investors Services previously reported a position in ESPR as recently as Q4 2025.

MML Investors Services first reported a position in ESPR in Q2 2024 and has held it in 8 quarters since. The position peaked at $79.6K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

MML Investors Services held 21,450 shares of Esperion Therapeutics worth $67.8K as of Q2 2026.
Esperion Therapeutics was a new MML Investors Services position in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #3211 holding.
MML Investors Services first reported a position in Esperion Therapeutics in Q2 2024 and has held it in 8 quarters since.
MML Investors Services's Esperion Therapeutics position peaked at $79.6K in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.